Edesa Biotech wins CHLA Award for Best BD Deal of 2017 and Dr. Par Nijhawan Inducted into the CHLA Hall of Fame
Published: Mar 06, 2018
MARKHAM, ON, March 6, 2018 /PRNewswire/ - Edesa Biotech Inc., a clinical-stage private company announced today it received the Best Business Development Deal of 2017 awarded by the Canadian Healthcare Licensing Association (CHLA). The award was accepted by Dr. Michael Brooks who stated that "It was gratifying to see the teams hard work pay off. Our team worked closely with Pharmascience Inc. in creating an innovative deal structure that helped all sides achieve their internal requirements. At the end we were able to raise our funding goals and also partner with a highly respected company".
The CHLA also inducted Edesa's founder and CEO, Dr. Par Nijhawan M.D., F.R.C.P.C, into its Hall of Fame. "This is truly an honour to be inducted into the Hall of Fame. This is a humbling experience as this acknowledgement speaks more to the fact that I have been very fortunate to have worked with brilliant colleagues, exceptional partners and outstanding investors", said Dr. Nijhawan.
About Edesa Biotech Inc.
Edesa Biotech is a clinical-stage private company focused on efficiently developing product candidates that address significant unmet medical needs. The initial focus is on developing novel, safe and potent alternatives to steroids for Allergic Contact Dermatitis, Hemorrhoids and Anal Fissures. Edesa Biotech's lead asset, EB01 is a novel non-steroidal anti-inflammatory molecule for the treatment of allergic contact dermatitis which has already demonstrated statistically significant improvements in multiple clinical studies.
Michael Brooks Ph.D., M.B.A., Vice President, Corporate Development, firstname.lastname@example.org, 905-475-1234, www.edesabiotech.com
SOURCE Edesa Biotech Inc.